InterVenn and Aranscia Expand Partnership for GlycoKnow Ovarian Cancer Test

July 06, 2026
InterVenn Biosciences and Aranscia have expanded their commercialization partnership to broaden access to the GlycoKnow Ovarian cancer diagnostic test, a blood-based liquid biopsy that helps distinguish malignant from benign pelvic masses.

InterVenn Biosciences and Aranscia announced in a press release an expansion of their commercialization partnership to increase access to the GlycoKnow Ovarian cancer diagnostic test.

The partnership extends InterVenn’s diagnostic solutions across Aranscia’s network of health systems, women’s health and oncology groups, and individual clinicians. GlycoKnow Ovarian is a proprietary blood-based liquid biopsy designed to help distinguish ovarian cancer from benign pelvic masses.

The test assists doctors in identifying benign cases, potentially reducing the number of unnecessary surgical procedures and associated risks. GlycoKnow Ovarian was developed and validated by InterVenn and is offered as a laboratory-developed test under CLIA certification and CAP proficiency standards. It has not been cleared or approved by the U.S. Food and Drug Administration.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

07/06
METiS TechBio Grants Global License for AI Designed T Cell Engager to Boulevard Bio
07/06
Orqa and Remote Robotic Systems Sign $150M Deal to Expand Drone and AI Production in Canada
07/06
Sabanto and Verdant Robotics Integrate Autonomous Tractor and Precision Application Systems
07/06
HiLabs and Harvard Researchers Partner to Study Ghost Networks in Medicare Advantage
07/06
SK Telecom Plans 15GW AI Data Center Program to Establish Korea as Regional Hub

More from: Life Sciences

07/06
METiS TechBio Grants Global License for AI Designed T Cell Engager to Boulevard Bio
07/06
Marley Health Launches Clinical Intelligence Platform for Veterinary Care
07/06
CollPlant Biotechnologies Announces $2.6 Million Private Placement
07/06
HiLabs and Harvard Researchers Partner to Study Ghost Networks in Medicare Advantage
07/06
MGI Tech and Shanghai AI Lab Introduce Physical AI Systems for Life Sciences

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

AI and the Law: Discussion Paper

This discussion paper explores the intersection of artificial intelligence and legal frameworks, addressing potential legal challenges posed by AI's autonomy, adaptiveness, and opacity. It examines issues such as liability gaps, causation, and the potential for granting AI systems legal personality, aiming to foster further discussion on AI's impact on law reform.

Read more

You May Also Like